A novel c-Met targeting antibody drug conjugate for NSCLC

被引：1
|
作者：
Li, Lingna
Fells, Cathrine
Guo, Julia
Muyot, Pia
Gros, Edwige
Zhang, Yanliang
Sun, Yingqing
Zhang, Hong
Fu, Yanwen
Zhu, Tong
Cao, Jian
Kaufmann, Gunnar
Chen, Gang
Miao, Zhenwei
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-3897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3897
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A novel antibody–drug conjugate targeting SAIL for the treatment of hematologic malignancies
    S Y Kim
    J-W Theunissen
    J Balibalos
    S Liao-Chan
    M C Babcock
    T Wong
    B Cairns
    D Gonzalez
    E H van der Horst
    M Perez
    Z Levashova
    L Chinn
    J A D‘Alessio
    M Flory
    A Bermudez
    D Y Jackson
    E Ha
    J Monteon
    M F Bruhns
    G Chen
    T-S Migone
    Blood Cancer Journal, 2015, 5 : e316 - e316
  • [42] Highly selective c-Met inhibitor tepotinib plus gefitinib is active in Asian patients with c-Met plus NSCLC
    Soo, R.
    Kim, D. -W.
    Yang, J. C. -H.
    Park, K.
    Stammberger, U.
    Xiong, H.
    Ihling, C.
    Wu, Y. -L.
    ANNALS OF ONCOLOGY, 2015, 26 : 143 - 143
  • [43] Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification
    Mazzotta, M.
    Filetti, M.
    Rossi, A.
    Roberto, M.
    Occhipinti, M.
    Pernazza, A.
    Di Napoli, A.
    Scarpino, S.
    Vecchione, A.
    Giusti, R.
    Marchetti, P.
    ANNALS OF ONCOLOGY, 2020, 31 (03) : 440 - 441
  • [44] Progress of antibody-drug conjugates (ADCs) targeting c-Met in cancer therapy; insights from clinical and preclinical studies
    Mer, Ali Hussein
    Mirzaei, Yousef
    Misamogooe, Fatemeh
    Bagheri, Nader
    Bazyari, Ahmadreza
    Keshtkaran, Zahra
    Meyfour, Anna
    Shahedi, Alireza
    Amirkhani, Zahra
    Jafari, Ameneh
    Barpour, Nesa
    Jahandideh, Saeed
    Rezaei, Behzad
    Nikmanesh, Yousef
    Abdollahpour-Alitappeh, Meghdad
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2024, 14 (11) : 2963 - 2988
  • [45] C-Met is a potential therapeutic target for antibody-drug conjugates in breast cancer
    Fu, Yanwen
    Gros, Edwige
    Lee, Alice
    Johnson, Kimberly
    Zhang, Hong
    Yalamanchili, Silpa
    Motamed, Kouros
    Chen, Gary
    Jones, Bryan
    Miao, David
    Kaufmann, Gunnar F.
    CANCER RESEARCH, 2015, 75
  • [46] Activation of c-Met by EGFR modulates invasive phenotypes in NSCLC
    Dulak, Austin M.
    Siegfried, Jill M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : S226 - S226
  • [47] Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A
    Breen, Laura
    Gaule, Patricia B.
    Canonici, Alexandra
    Walsh, Naomi
    Collins, Denis M.
    Cremona, Mattia
    Hennessy, Bryan T.
    Duffy, Michael J.
    Crown, John
    O' Donovan, Norma
    Eustace, Alex J.
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1365 - 1372
  • [48] First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
    Strickler, John H.
    Weekes, Colin D.
    Nemunaitis, John
    Ramanathan, Ramesh K.
    Heist, Rebecca S.
    Morgensztern, Daniel
    Angevin, Eric
    Bauer, Todd M.
    Yue, Huibin
    Motwani, Monica
    Parikh, Apurvasena
    Reilly, Edward B.
    Afar, Daniel
    Naumovski, Louie
    Kelly, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (33) : 3298 - +
  • [49] Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A
    Laura Breen
    Patricia B. Gaule
    Alexandra Canonici
    Naomi Walsh
    Denis M. Collins
    Mattia Cremona
    Bryan T. Hennessy
    Michael J. Duffy
    John Crown
    Norma O’ Donovan
    Alex J. Eustace
    Investigational New Drugs, 2020, 38 : 1365 - 1372
  • [50] Novel targets mediating resistance to EGFR/c-Met tyrosine kinase inhibitors in NSCLC.
    Jacobs, Ryan
    Fong, Jason
    Moravec, David
    Botting, Greg
    Bomgarden, Ryan
    Rogers, John
    Viner, Rosa
    Blank, Michael
    Puri, Neelu
    CANCER RESEARCH, 2013, 73 (08)
12345